Development of new non-invasive tests for colorectal cancer screening: The relevance of information on adenoma detection

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2864-2874

  Haug, Ulrike ^a   Knudsen, Amy B ^b   Lansdorp Vogelaar, Iris ^c   Kuntz, Karen M ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

blood test; colorectal cancer; screening; stool test

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MIDDLE AGED; NON INVASIVE MEASUREMENT; OCCULT BLOOD TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ADENOMA; CHEMISTRY; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; EARLY DIAGNOSIS; ECONOMICS; MALE; MASS SCREENING; OCCULT BLOOD; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL;

ALPHA-GUAIACONIC ACID; FURAN DERIVATIVE; PHENOL DERIVATIVE;

ADENOMA; AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FURANS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; OCCULT BLOOD; PHENOLS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84927574569     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29343     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the fecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007; 1: CD001216.
3. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-33.
4. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial-SCORE. J Natl Cancer Inst 2011; 103: 1310-22.
5. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012; 366: 2345-57.
6. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.
7. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56: 210-4.
8. Macrae FA, St John DJ,. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-98.
9. Ahlquist DA,. Molecular detection of colorectal neoplasia. Gastroenterology 2010; 138: 2127-39.
10. Haug U, Hundt S, Brenner H,. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010; 105: 682-90.
11. Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000; 284: 1954-61.
12. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 659-69.
13. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, et al. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med 2010; 153: 368-77.
14. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst 2010; 102: 1238-52.
15. Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making 2011; 31: 530-9.
16. van Ballegooijen M, Rutter CM, Knudsen AB, et al. Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making 2011; 31: 540-9.
17. Surveillance Epidemiology and End Results (SEER) Program. SEER∗ Stat database: incidence-SEER 9 Regs public-use, November 2003 Sub (1973-2001). Available at: www.seer.cancer.gov. Last accessed September 1, 2014.
18. National Center for Health Statistics Databases-publications and information products-life tables. Available at: http://www.cdc.gov/nchs/products/life-tables.htm. Last accessed September 1, 2014.
19. Clark JC, Collan Y, Eide TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer. Int J Cancer 1985; 36: 179-86.
20. Blatt LJ,. Polyps of the colon and rectum: incidence and distribution. Dis Colon Rectum 1961; 4: 277-82.
21. Vatn MH, Stalsberg H,. The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 1982; 49: 819-25.
22. Jass JR, Young PJ, Robinson EM,. Predictors of presence, multiplicity, size and dysplasia of colorectal adenomas. A necropsy study in New Zealand. Gut 1992; 33: 1508-14.
23. Johannsen LG, Momsen O, Jacobsen NO,. Polyps of the large intestine in Aarhus, Denmark. An autopsy study. Scand J Gastroenterol 1989; 24: 799-806.
24. Bombi JA,. Polyps of the colon in Barcelona, Spain. Cancer 1988; 61: 1472-76.
25. Williams AR, Balasooriya BA, Day DW,. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut 1982; 23: 835-42.
26. Rickert RR, Auerbach O, Garfinkel L, et al. Adenomatous lesions of the large bowel. Cancer 1979; 43: 1847-57.
27. Chapman I,. Adenomatous polypi of large intestine: incidence and distribution. Ann Surg 1963; 157: 223-26.
28. Arminski TC, McLean DW,. Incidence and distribution of adenomatous polyps of the colon and rectum based on 1.000 autopsy examinations. Dis Colon Rectum 1964; 7: 249-61.
29. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006; 130: 1872-85.
30. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin 2006; 56: 143-59.
31. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008: 58: 130-60.
32. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95.
33. Young GP, Fraser CG, Halloran SP, et al. Guaiac based faecal occult blood testing for colorectal cancer screening: an obsolete strategy? Gut 2012; 61: 959-60.
34. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006; 101: 343-50.
35. Howlader N, Noone AM, Krapcho M, et al., eds. SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011.
36. Gellad ZF, Stechuchak KM, Fisher DA, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol 2011; 106: 1125-34.
37. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-55.
38. Haug U, Hundt S, Brenner H,. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010; 105: 682-90.
39. Homepage of the Organisation for Economic Co-operation and Development (OECD): Available at: http://www.oecd.org/document/30/0,3746, en-2649-37407-12968734-1-1-1-37407,00.html; accessed October 8th, 2012.
40. Center MM, Jemal A, Smith RA, et al. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-78.
41. Hassan C, Benamouzig R, Spada C, et al. Cost effectiveness and projected national impact of colorectal cancer screening in France. Endoscopy 2011; 43: 780-93.
42. Sharp L, Tilson L, Whyte S, et al. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. Br J Cancer 2012; 106: 805-16.
43. Maroun J, Ng E, Berthelot JM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can 2003; 24: 91-101.
44. Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut 2012; 61: 1036-40.
45. Kronborg O, Jørgensen OD, Fenger C, et al. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds. Scand J Gastroenterol 2004; 39: 846-51.